N/A N=3 Spinal Cord Stimulation in Spinal Muscular Atrophy
Spinal Muscular Atrophy Type 3 · Spinal Muscular Atrophy Type 4
Primary: Muscle Weakness — 2; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=15 Transcutaneous Electrical Spinal Stimulation to Restore Upper Extremity Functions in Spinal Cord Injury
Spinal Cord Injury Cervical · Upper Extremity Dysfunction
Primary: Graded and Redefined Assessment of Strength, Sensibility and Prehension Test (GRASSP Test) — 4.5; 19.4 score change before and after — p=<0.000
Phase 2 N=67 Mechanistic Approach to Preventing Atrophy and Restoring Function in Older Adults
Muscle Atrophy · Quality of Life
Primary: MRI Quadriceps Involved Leg — 43.87; 38.31 AU — p=.03
Phase 4 N=36 Spinal Versus General Anesthesia With Popliteal and Adductor Canal Blocks for Ambulatory Foot and Ankle Surgery.
Nerve Block · General Anesthesia · Spinal Anesthesia
Primary: Time Until Patient is Ready for Discharge From Post-Anesthesia Care Unit (PACU) to Home. — 81; 43.5 Minutes
Phase 2 N=14 Study to Evaluate Sodium Phenylbutyrate in Pre-symptomatic Infants With Spinal Muscular Atrophy
Spinal Muscular Atrophy
Primary: Safety and Tolerability of Sodium Phenylbutyrate in Neonates and Infants With SMA — 1; 8; 0; 1 Participants
Phase 2 N=58 An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy
Spinal Muscular Atrophy · Spinal Muscular Atrophy Type 3 · Spinal Muscular Atrophy Type 2
Primary: Cohort 1: Change From Baseline in the Revised Hammersmith Scale (RHS) Total Score at Day 364 (Visit 15) [Month 12] — -0.1; 0.0 score on a scale
Phase 2 N=29 A Pilot Therapeutic Trial Using Hydroxyurea in Type I Spinal Muscular Atrophy Patients
Muscular Atrophy, Spinal
Primary: Safety: Frequency of Adverse Events/Lab Abnormalities
Phase 2 N=13 An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA)
Spinal Muscular Atrophy
Primary: Number of Participants With Dose Limiting Toxicities (DLT) in Part 1 - Safety Analysis Set (SAS) — 0; 0; 0; 0 Participants
Phase 3 N=2 Single-Dose Gene Replacement Therapy Using for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies
Spinal Muscular Atrophy Type I
Primary: Number of Participants Who Achieved Sitting Alone for at Least 10 Seconds — 1 Participants
Phase 2 N=34 An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy
Spinal Muscular Atrophy
Primary: Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuations Due to AEs, and Highest Severity of AEs — 8; 6; 9; 9 Participants
Phase 2 N=21 A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (SMA)
Spinal Muscular Atrophy
Primary: Percent of Participants Who Achieved Improvement in Motor Milestones as Assessed by Section 2 of the HINE at the Last Visit — 25.0; 68.8 Percent of participants
Early Phase 1 N=229 Comparison of 0.1 and 0.05mg Intrathecal Morphine for Post-cesarean Analgesia.
Cesarean Section
Primary: Time to First Narcotic Rescue Dose in the First 24 Hours Post-cesarean Delivery. — NA; 23.5 hours
Phase 3 N=33 Single-Dose Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1
SMA
Primary: Number of Participants Who Achieve Independent Sitting for at Least 10 Seconds — 14 Participants
Phase 2 N=27 A Pilot Therapeutic Trial Using Hydroxyurea in Type II and Type III Spinal Muscular Atrophy Patients
Muscular Atrophy, Spinal
Primary: Efficacy: Functional Motor Testing, Including Gross Motor Function Measure (GMFM) and Timed Motor Tests
Phase 2 N=13 Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients
Muscular Atrophy, Spinal
Primary: Hammersmith Functional Motor Scale Expanded (HFMSE) Summary Statistics and Mixed Model Analysis — 0.208; -0.583 Overall Score — p=0.0083